Compare IDEXX Laboratories, Inc. (IDXX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while YieldMax Universe Fund of Option Income ETFs trades at $7.64. The key difference: IDEXX Laboratories, Inc. is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| IDXX | YMAX | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $13.26 |
52-Week Low | $526.44 | $7.27 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
YMAX trades at $7.63, down 1.04% in the past 24 hours, with technical indicators showing a bullish overall signal but bearish moving averages. The fund has announced consistent weekly dividend distributions, though recent news highlights concerns over fee structures impacting payouts. Key support is at $7, with resistance at $8.
The outlook for YMAX hinges on its ability to sustain dividend yields amid fee pressures; opportunities include high income generation, but risks involve cost inefficiencies and market volatility. Analyst sentiment is mixed, balancing yield appeal against structural drawbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
